GoKawiil
Tech News
The FDA announced a new label warning for GLP-1 medications including Ozempic and Zepbound, flagging a rare eye condition that can cause sudden vision changes. The agency says the condition carries a risk of permanent damage in some patients.
Novo Nordisk, the Danish pharmaceutical company known for Ozempic and Wegovy, is rebranding itself as simply 'Novo' starting this week. The move shifts the company's public identity toward a shorter, more casual name as it markets directly to consumers rather than solely to healthcare providers.
The Guardian gathered reader accounts describing how GLP-1 drugs like Wegovy, Ozempic and Mounjaro have reshaped family dynamics, with many users hiding their use out of shame. Several described feeling they had 'cheated' at weight loss, straining relationships with partners, children and friends who didn't know about the medication.
Researchers publishing in Nature on September 2 found that older female mice given a GLP-1 obesity drug lived longer than untreated mice and showed slower onset of several biological markers linked to aging. The finding builds on earlier mouse studies suggesting GLP-1 medications, typically used for obesity and type 2 diabetes, may have broader anti-aging effects beyond weight loss.